Author

Linda V. Kessler

Kura Oncology (United States)ORCID 0000-0002-8677-3252Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1

Frequent Co-Authors

Francis J. BurrowsiD· 2 shared Abhinav DeoliD· 1 shared Alison Elizabeth SmithiD· 1 shared Amitava MitraiD· 1 shared Amro AboukameeliD· 1 shared Asfar Sohail AzmiiD· 1 shared Ayuna JombikiD· 1 shared Hetika Vora PateliD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Francis J. BurrowsORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Combined Menin and XPO1 inhibition drive synergistic antileukemic activity in KMT2Ar and NPM1-m AML

Md. Hafiz Uddin, Sandhya Dhiman, Yufen Han, Amro Aboukameel, Vikram Dhillon, Jeff Justin Aguilar, Steven A. Buck, Abhinav Deol, Julie L. Boerner, Lisa Polin, Linda V. Kessler, Francis Burrows, Jay Yang, Asfar Sohail Azmi, Jaroslaw Pawel Maciejewski, , Suresh Kumar Balasubramanian

This study shows that combining Menin and XPO1 inhibitors synergistically inhibits KMT2A-r and NPM1-m AML cell growth and improves survival in xenograft models.

bioRxiv · Mar 13, 2026 · PreprintCancer Biology

The farnesyl transferase inhibitor KO-2806 re-sensitizes relapsing tumors to RAS inhibition

Hetika Vora Patel, Alison Elizabeth Smith, Stacia Chan, Jovylyn Gatchalian Gasendo, Ayuna Jombik, John Edward Greer, Tejas Samantaray, Linda V. Kessler, Amitava Mitra, Xuefeng Zhu, Yahu A. Liu, Francis J. Burrows, Shivani Malik

This paper identifies mTORC1 activity as a driver of resistance to RAS inhibitors and shows that KO-2806 re-sensitizes resistant tumors to RAS inhibition.

Cancer Research · Feb 9, 2026Peer-reviewedCancer Biology